A Phase II Study of Osimertinib in Patients with Advanced-Stage Non-Small Cell Lung Cancer following Prior Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor (EGFR TKI) Therapy with EGFR and T790M Mutations Detected in Plasma Circulating Tumour DNA (PLASMA Study)

SIMPLE SUMMARY: Lung cancers with EGFR gene mutations treated with targeted therapy often develop another genetic change (T790M) that allows them to be treated with a further targeted therapy, Osimertinib, with good outcomes. The gold standard for the detection of these changes is to perform a tissu...

Descripción completa

Detalles Bibliográficos
Autores principales: Ang, Yvonne L. E., Zhao, Xiaotian, Reungwetwattana, Thanyanan, Cho, Byoung-Chul, Liao, Bin-Chi, Yeung, Rebecca, Loong, Herbert H., Kim, Dong-Wan, Yang, James Chih-Hsin, Lim, Sun Min, Ahn, Myung-Ju, Lee, Se-Hoon, Suwatanapongched, Thitiporn, Kongchauy, Kanchaporn, Ou, Qiuxiang, Yu, Ruoying, Tai, Bee Choo, Goh, Boon Cher, Mok, Tony S. K., Soo, Ross A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10605750/
https://www.ncbi.nlm.nih.gov/pubmed/37894366
http://dx.doi.org/10.3390/cancers15204999

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10605750/
https://www.ncbi.nlm.nih.gov/pubmed/37894366
http://dx.doi.org/10.3390/cancers15204999

Ejemplares similares